An interventional study of Resistance Exercise Program and Nutrition and Exercise Counseling in Muscle Mass and Strength, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Sarcopenia with a site in United States — 36 open to participants now, 46 under way, 1 of them phase 3. Sarcopenia · United States.
Among the 187 studies in Sarcopenia with a site in United States, this one is the 73rd largest by planned enrollment of the 146 interventional ones that give a count, is one of 14 that started in 2026, is one of 101 with no phase, reaches primary completion later than 35 of the 45 other live ones, and was the 177th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →36 of the 187 studies in Sarcopenia with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+
Kennesaw State University · Sites in United States
Ages 65–85 · Healthy volunteers
Health Discovery Labs · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 24 · Phase 3 3 · Phase 4 5
First in 1995; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 40 across the 146 interventional studies, 70 across the 40 observational. Of the 127 that completed or were terminated, 44 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 187 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 3 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
17 of the studies in Sarcopenia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
| NCT07421648SynchroHealth LLCBandPass: A Remote Monitoring System for Sarcopenia and Functional Decline Phase II Aim 4 | 2026-12 |
| NCT06722508University of California, DavisExercise and Nutritional Prehabilitation for Head and Neck Cancer Patients | 2026-12 |
| NCT07029243University of California, San FranciscoPrehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis | 2026-12 |
| NCT06628349Texas A&M UniversityPrandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 187 studies in Sarcopenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Estrogen-dominant gender-affirming hormone therapy (GAHT) is standard of care for transgender women and gender-diverse individuals and typically consists of estrogen together with anti-androgen/ testosterone therapy. Estrogen and testosterone balance influences fat and muscle mass, muscular strength and the development of sarcopenia. Sarcopenia, a condition characterized by the loss of muscular mass, strength, and function, in turn, is associated with increased mortality and adverse health outcomes. Estrogen-dominant GAHT may have deleterious effects on body composition and muscular performance that place TGD individuals at-risk for sarcopenia. As part of NCT04128488, our investigative team found that appendicular lean mass (ALM)/ height2 decreases after estrogen-based GAHT, thereby portending a higher risk for sarcopenia after GAHT. Early recognition of the changes in body composition and muscular performance leading to sarcopenia are critical, providing potential avenues to intervene and abrogate untoward downstream health effects. A promising intervention is resistance exercise, which has been shown in select populations to improve muscular mass and strength and reduce fat mass, and, thus, mitigate progression to sarcopenia in at-risk populations. For this prospective, pilot clinical trial, investigators will enroll participants who are about to be initiated or recently initiated (3 months ago or less) on estrogen-dominant gender-affirming hormone therapy. Investigators will be randomizing participants 1:1 to either an at-home resistance exercise intervention or no exercise intervention (nutritional and exercise counseling only) for 12 weeks and assess muscle mass, strength, and function both before and after this 12-week period. The exercise intervention group will be provided with the necessary materials to complete the exercise program along with weekly virtual visits with our study team in order to learn their assigned exercises for the week. Further, survey tools will be administered to ascertain whether the resistance exercise intervention may affect gender congruence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will be randomized to a 12-week at-home resistance exercise program.
Behavioral: Resistance Exercise Program · Behavioral: Nutrition and Exercise Counseling
Participants in this arm will receive educational counseling on nutrition and exercising.
Behavioral: Nutrition and Exercise Counseling
Participants will initiate this program within approximately 3 months of starting their gender-affirming hormone therapy and will be instructed to complete resistance exercises for three 60-minute sessions per week for 12 weeks. Participants will have a weekly video call to demonstrate the exercises for that week, have a supervised training session to ensure exercises are performed safely and as instructed, monitor their continued participation in the intervention, and address any questions/issues that arise as part of the program. Participants will be provided with resistance bands, a TRX suspension trainer, and dumbbell weights in order to complete the resistance exercises for the program. Examples of how each exercise can be modified depending on a participant's limitations will also be provided as needed. The study team will ascertain whether they can progress to the next week's exercises depending on their ability to achieve the number of repetition's of the prior week.
Participants will undergo lifestyle counseling related to optimization of their nutrition and exercise regimen.
Appendicular lean mass/height^2
Change in appendicular lean mass/height\^2 (kg/m\^2) assessed via whole body DEXA in resistance exercise group
Time frame: 12 weeks
Gender congruence
Change in gender congruence (utilizing the total scale score from Transgender Congruence Scale) in resistance exercise group
Time frame: 12 weeks
Visceral adipose tissue mass
Change in total visceral adipose tissue mass (g) assessed using whole body DEXA in resistance exercise group
Time frame: 12 weeks
Visceral adipose tissue volume
Change it total visceral adipose tissue volume (cm3) assessed using whole body DEXA in resistance exercise group
Time frame: 12 weeks
Total fat mass
Change in total fat mass (kg) assessed using whole body DEXA in resistance exercise group
Time frame: 12 weeks
Total lean body mass
Change in total lean body mass (kg) assessed using whole body DEXA in resistance exercise group
Time frame: 12 weeks
Muscular function
Change in muscular function assessed via the 5 X sit to stand test (sec) in resistance exercise group
Time frame: 12 weeks
Hand-grip strength
Change in hand-grip strength (kg) assessed using a Lafayette Hand Grip Dynamometer in resistance exercise group
Time frame: 12 weeks
Horizontal shoulder adduction strength
Change in horizontal shoulder adduction strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group
Time frame: 12 weeks
Shoulder extension strength
Change in shoulder extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group
Time frame: 12 weeks
Elbow flexion strength
Change in elbow flexion strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group
Time frame: 12 weeks
Elbow extension strength
Change in elbow extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group
Time frame: 12 weeks
Knee extension strength
Change in knee extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group
Time frame: 12 weeks
Knee flexion strength
Change in knee flexion strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group
Time frame: 12 weeks
Hip extension strength
Change in hip extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer in resistance exercise group
Time frame: 12 weeks
Resting energy expenditure
Change in resting energy expenditure (kcal/day) assessed using a metabolic cart in the resistance exercise group
Time frame: 12 weeks
Resting metabolic rate
Change in resting metabolic rate (kcal/day) assessed using a metabolic cart in resistance exercise group
Time frame: 12 weeks
Respiratory quotient
Change in respiratory quotient (ratio) assessed using a metabolic cart in the resistance exercise group
Time frame: 12 weeks
Between-group change in appendicular lean body mass/ height^2
Between-group change in appendicular lean body mass/ height\^2 (kg/m\^2) assessed via whole body DEXA
Time frame: 12 weeks
Between-group change in total visceral adipose tissue mass
Between-group change in total visceral adipose tissue mass (g) assessed using whole body DEXA
Time frame: 12 weeks
Between-group change in visceral adipose tissue volume
Between-change in total visceral adipose tissue volume (cm3) assessed using whole body DEXA
Time frame: 12 weeks
Between-group change in total fat mass
Between-change in total fat mass (kg) assessed using whole body DEXA
Time frame: 12 weeks
Between-group change in total lean body mass
Between-group change in total lean body mass (kg) assessed using whole body DEXA
Time frame: 12 weeks
Between-group change in muscular function via the 5x sit to stand test
Between-group change in muscular function assessed via the 5 X sit to stand test (sec)
Time frame: 12 weeks
Between-group change in hand-grip strength
Between-group change in hand-grip strength (kg) assessed using a Lafayette Hand Grip Dynamometer
Time frame: 12 weeks
Between-group change in horizontal shoulder adduction strength
Between-group change in horizontal shoulder adduction strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer
Time frame: 12 weeks
Bwtween-group change in shoulder extension strength
Between-group change in shoulder extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer
Time frame: 12 weeks
Between-group change in elbow flexion strength
Between-group change in elbow flexion strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer
Time frame: 12 weeks
Between-group change in elbow extension strength
Between-group change in elbow extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer
Time frame: 12 weeks
Between-group change in knee extension strength
Between-group change in knee extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer
Time frame: 12 weeks
Between-group change in knee flexion strength
Between-group change in knee flexion strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer
Time frame: 12 weeks
Between-group change in hip extension strength
Between-group change in hip extension strength (kgf) assessed using a Hogan Scientific MicroFET2 Handheld dynamometer
Time frame: 12 weeks
Between-group change in resting energy expenditure
Between-group change in resting energy expenditure (kcal/day) assessed using a metabolic cart
Time frame: 12 weeks
Between-group change in resting metabolic rate
Between-group change in resting metabolic rate (kcal/day) assessed using a metabolic cart
Time frame: 12 weeks
Between-group change in respiratory quotient
Between-group change in respiratory quotient (ratio) assessed using a metabolic cart
Time frame: 12 weeks
Appearance congruence
Change in appearance congruence (utilizing the appearance congruence subscale score from Transgender Congruence Scale) in resistance exercise group
Time frame: 12 weeks
Gender identity acceptance
Change in gender identity acceptance (utilizing the gender identity acceptance subscale score from Transgender Congruence Scale) in resistance exercise group
Time frame: 12 weeks
Between-group change in appearance congruence
Between-group change in appearance congruence (utilizing the appearance congruence subscale score from Transgender Congruence Scale)
Time frame: 12 weeks
Between-group change in gender identity acceptance
Between-group change in gender identity acceptance (utilizing the gender identity acceptance subscale score from Transgender Congruence Scale)
Time frame: 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 23 months after the start.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 23 months is above that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →